Graves Ophthalmopathy clinical trials

The registry lists 199 studies for Graves Ophthalmopathy across more than 10 countries. 58 are recruiting or about to start. 191 of them are mainly about Graves Ophthalmopathy (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-02.

Get an email when these change. Save the Graves Ophthalmopathy studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 80
Recruiting: 38
Status unknown: 25
Not yet recruiting: 18
Terminated: 15
Active, not recruiting: 13

Phase

Phase 3: 52
Phase 2: 40
Phase 4: 25
Phase 1: 21
Early Phase 1: 2

Where

China: 55
United States: 53
Italy: 24
Spain: 23
Germany: 20
United Kingdom: 19

Who runs them

Amgen (14) · Sun Yat-sen University (14) · University of Pisa (11) · Viridian Therapeutics, Inc. (9) · Shanghai Changzheng Hospital (7) · Innovent Biologics (Suzhou) Co. Ltd. (6) · Minghui Pharmaceutical (Hangzhou) Ltd (6) · Immunovant Sciences GmbH (5)

What is being tested here

Drugs under test in Graves Ophthalmopathy studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
IBI311	4	4	8
MHB018A	4	6	6
Atorvastatin	4	1	5
Methylprednisolone	3	2	7
Teprotumumab	2	3	12
Linsitinib	2	3	3
Sirolimus	2	0	3
AVE1642	1	4	5
Tocilizumab	1	1	4
Doxycycline	1	0	3

Drug classes tested here Corticosteroids 6 open · Statins 5 open · Tyrosine kinase inhibitors (TKIs) 3 open · Antithyroid drugs 1 open

Coming up

20phase 3 studies under way

20studies finish main data collection within a year7 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Dec 2026MHB018A Treatment in Patients With Active Thyroid Eye Disease · Phase 3 · Minghui Pharmaceutical (Hangzhou) Ltd
Dec 2026A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease · Phase 3 · Innovent Biologics (Suzhou) Co. Ltd.
Jan 2027Treatment of Graves´ophthalmopathy with Simvastatin (GO-S) · Phase 3 · Lund University
Mar 2027A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease · Phase 3 · Zai Lab (Shanghai) Co., Ltd.
Apr 2027A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Active Thyroid Eye Disease · Phase 3 · Beijing Kanghong Biological Medicine Co., Ltd.
May 2027A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Inactive Thyroid Eye Disease · Phase 3 · Beijing Kanghong Biological Medicine Co., Ltd.
Aug 2027MHB018A Treatment in Patients With Chronic Thyroid Eye Disease · Phase 3 · Minghui Pharmaceutical (Hangzhou) Ltd
Dec 2026Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease. · Peking University Third Hospital
Jan 2027A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease · Amgen
Apr 2027An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to Teprotumumab · Viridian Therapeutics, Inc.

Who these studies take

Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger. 1 (3%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 9 (24%) take healthy volunteers.

Recruiting studies that take each age, of 38
Age	Women	Men
10	1 (3%)	1 (3%)
18	37 (97%)	37 (97%)
30	38 (100%)	38 (100%)
40	38 (100%)	38 (100%)
50	38 (100%)	38 (100%)
65	38 (100%)	38 (100%)
75	33 (87%)	33 (87%)
85	10 (26%)	10 (26%)

Across all 199 studies, recruiting or not: 39% stop at 75 or younger and 8% at 65; 3% take children; 1% are for women only and 0% for men only; 14% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Graves Ophthalmopathy studies take

Of 29 phase 3 interventional studies under Graves Ophthalmopathy, half reached primary completion within 18 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 3	18 mo14–25 · 29 studies	—	—
Observational	47 mo43–59 · 20 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 14, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 199. Browse all 199 → or search them.